Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
2019 · New England Journal of Medicine · 5,793 citations
https://doi.org/10.1056/nejmoa1811744
H
Hiddo J.L. Heerspink
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.1K
Papers
62.8K
Citations
118
h-index
496
i10-index
Hiddo J.L. Heerspink is an academic researcher from University Medical Center Groningen. The author has contributed to research in topics: Diabetes Treatment and Management & Chronic Kidney Disease and Diabetes & Pancreatic function and diabetes. The author has an h-index of 118, co-authored 919 publications.
ORCID: 0000-0002-3126-3730Papers by this author
worksDapagliflozin in Patients with Chronic Kidney Disease
2020 · New England Journal of Medicine · 4,895 citations
https://doi.org/10.1056/nejmoa2024816
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
2012 · The Lancet · 1,351 citations
https://doi.org/10.1016/s0140-6736(12)61350-6
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
2022 · Kidney International · 1,080 citations
https://doi.org/10.1016/j.kint.2022.06.008
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
2022 · The Lancet · 918 citations
https://doi.org/10.1016/s0140-6736(22)02074-8
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
2017 · The Lancet · 895 citations
https://doi.org/10.1016/s0140-6736(17)30788-2
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat